Minireviews
Copyright ©The Author(s) 2016.
World J Gastrointest Pharmacol Ther. Nov 6, 2016; 7(4): 524-530
Published online Nov 6, 2016. doi: 10.4292/wjgpt.v7.i4.524
Table 1 Laboratory tests to determine risk of myelotoxicity and hepatotoxicity during initiation of thiopurine therapy
Hematologic parameters
Hemoglobin
White blood cell count
Platelet count
Hepatic parameters
Alkalic phosphatase
Gamma glutamyl transpeptidase
Alanine aminotransferase
Other parameters
Creatinine
C-reactive protein
Table 2 Interpretation of metabolite levels in patients with inflammatory bowel disease treated with azathioprine or mercaptopurine
6-TGN (pmol/8 × 108 RBC)6-MMP (pmol/8 × 108 RBC)Non-responseAdverse event (dose-dependent)Recommendation
<< 230<< 5700Non-complianceNot expectedGain compliance
< 230< 5700Non-compliance/under dosingNot expectedGain compliance/increase dose1
230-400< 5700Possible resistance to thiopurine therapyNot expectedIncrease dose1 or change therapy2
> 400< 5700Therapy resistanceMyelotoxicityChange therapy2
< 230>> 5700ShuntingMyelotoxicityConsider allopurinol3 or switch to TG4
< 230> 5700ShuntingHepatotoxicityConsider allopurinol, 5-ASA or switch to TG
230-400> 5700Possible resistance to thiopurine therapyHepatotoxicityConsider allopurinol3 or 5-ASA
> 400> 5700Therapy resistanceHepatotoxicityChange therapy2
MyelotoxicityDecrease dose5